Alamar Biosciences NULISAseq Mouse Panel 120 for protein biomarker analysis

Alamar Biosciences has launched the NULISAseq Mouse Panel 120 — an innovative biomarker profiling solution that provides comprehensive coverage of protein targets for expression analysis in mouse models. Designed to facilitate biomedical research and preclinical development studies, the cutting-edge panel analyses 120 proteins covering key pathways in inflammation, neurodegeneration and immuno-oncology.

The multiplex panel encompasses a wide selection of proteins essential for studying key biological pathways in preclinical models. It provides broad coverage of mouse protein targets, including a specific focus on neurology content. This is important for researchers studying neurodegenerative diseases and the neurological effects of potential treatments, with the potential to help uncover new insights into the mechanisms of dementia and traumatic brain injury.

Built on Alamar’s novel multiplexing technology, the panel offers researchers a high-sensitivity, high-throughput solution to uncover complex biological mechanisms. Its attomolar (fg/mL) sensitivity and 10 logs of dynamic range allow for the detection of a wide range of proteins found in mouse plasma, even those that are low in abundance, such as p-tau217, from as little as 5 µL sample input.